Key Highlights
- Stevanato Group (NYSE:STVN) fell about 24% to 26% in the November 3, 2026 session, with one morning snapshot at USD 14.63 against a USD 19.74 close on November 2.
- Third-quarter Revenue was EUR 326.1 million against about EUR 320.9 million expected, up 8%, and adjusted EPS of EUR 0.16 matched analyst estimates.
- Management guided only low single-digit revenue growth for 2027 and kept 2026 revenue guidance at EUR 1.26 billion to EUR 1.28 billion.
- GLP-1 products made up about 17% to 18% of third-quarter revenue, while Demand from other biologic drugs grew more than 30%, according to published coverage.
What Stevanato Reported
Stevanato Group (NYSE:STVN) supplies glass vials, syringes and drug-delivery devices to pharmaceutical companies. Its third-quarter report on November 3, 2026 showed revenue of EUR 326.1 million, ahead of the roughly EUR 320.9 million analysts expected, and adjusted EPS of EUR 0.16, in line with estimates. The headline numbers were not the problem. The market reacted to the outlook, because the company expects only low single-digit revenue growth in 2027 while holding its 2026 revenue range unchanged. The company kept 2026 revenue guidance at EUR 1.26 billion to EUR 1.28 billion, so the base year is not in doubt; the debate is about growth beyond it.
Order Intake and the GLP-1 Mix
Published coverage says new orders improved during the quarter but ended below the company's signed-order targets, which is a leading indicator for next year. GLP-1 customers accounted for about 17% to 18% of third-quarter revenue, and management said lower GLP-1 revenue was offset by other biologic drugs growing more than 30%. For a supplier, order timing matters more than quarterly sales, because syringe and vial capacity is committed ahead of customer launches. Stevanato (NYSE:STVN) now has to show that orders convert into 2027 sales at a faster pace than the guidance implies. In plain terms, a supplier of this kind is paid when customers Fill and ship drugs, so a slower order book usually shows up as softer sales a few quarters later. The company said new orders improved during the quarter, so the direction is positive even if the level fell short.
Size of the Move and the Risks
Sources differ on the drop. One snapshot showed a fall of about 25.9% in morning trading on Volume near four times the three-month average, a Market Value near USD 4 billion, while another report cited about 24%, so treat the figure as a range. The USD 14.63 level is intraday, not a close. Risks include customer concentration in obesity drugs, price pressure on injectable devices, capacity costs and slower biologic launches. Investors should read the 2027 commentary alongside any updated order data in coming quarters, and they should not assume a rebound or a further decline. A fall of this size can also reflect positioning, since a stock that rallies into Earnings has more room to disappoint. Prices in the first sessions after a guidance reset can move several points in either direction as analysts update their models.
Where Things Stand
Stevanato Group (NYSE:STVN) sank nearly 25% because a revenue beat was overshadowed by a low single-digit growth view for 2027 and signed orders that ended the quarter below target. The GLP-1 share of revenue, about 17% to 18%, is meaningful but not dominant, and other Biologics are growing faster. The next catalysts are fourth-quarter results, any order updates and whether the 2026 revenue range of EUR 1.26 billion to EUR 1.28 billion holds.






Please wait processing your request...